secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001558370-22-011887
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M
-----------------------------------------------------------------------------

- Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.
- GAAP net loss of $45.5M ($0.96 EPS) vs loss of $17.5M ($0.38) in Q2 2021; includes $10M IPR&D charge for iVeena licensing.
- Non-GAAP net loss of $39.1M ($0.83) vs $10.1M ($0.22) in prior year.
- Raised 2022 net sales guidance to $275-280M from prior $270-275M.
- Ended Q2 with ~$400M cash and short-term investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/0001558370-22-011887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/gkos-20220803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer